833 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services https://seekingalpha.com/article/4234405-week-review-yantais-mabplex-raises-59-million-expand-cdmo-services?source=feed_sector_healthcare Jan 20, 2019 - Luye Pharma out-licensed mainland China marketing rights for its anti-cholesterol Xuezhikang capsules to AstraZeneca China.Ironwood Pharma reported that China approved its treatment for irritable bowe
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY http://www.zacks.com/stock/news/348355/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny?cid=CS-ZC-FT-348355 Jan 18, 2019 - Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate http://www.zacks.com/stock/news/348241/immunomedics-gets-crl-from-fda-for-breast-cancer-candidate?cid=CS-ZC-FT-348241 Jan 18, 2019 - Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
NVS or AZN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/348018/nvs-or-azn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-348018 Jan 17, 2019 - NVS vs. AZN: Which Stock Is the Better Value Option?
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C http://www.zacks.com/stock/news/347742/ironwoods-irwd-linzess-gets-approval-in-china-for-ibs-c?cid=CS-ZC-FT-347742 Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Why AbbVie Believes In Life After (Humira's) Death https://seekingalpha.com/article/4233472-abbvie-believes-life-humiras-death?source=feed_sector_healthcare Jan 15, 2019 - ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.U.S. biosimilars to Humira will enter in 2023, though a competitor is tr
Dynavax Projects HEPLISAV-B Inflection In 2019, While CEO Eddie Gray Continues To Search For SD-101 Partners https://seekingalpha.com/article/4233324-dynavax-projects-heplisav-b-inflection-2019-ceo-eddie-gray-continues-search-sdminus-101?source=feed_sector_healthcare Jan 14, 2019 - Dynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~$3.7M.2018 was a
What's in Store for Merck in 2019 After a Solid Run in '18? http://www.zacks.com/stock/news/347164/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18?cid=CS-ZC-FT-347164 Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff http://www.zacks.com/stock/news/346023/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff?cid=CS-ZC-FT-346023 Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate http://www.zacks.com/stock/news/345809/pharma-stock-roundup-bmy-to-buy-celg-for-%2474b-mrk-gets-rights-to-nash-candidate?cid=CS-ZC-FT-345809 Jan 04, 2019 - Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.

Pages: 123456...84

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Astrazeneca PLC
AZN - Google Finance https://www.google.com/finance?q=AZN Industry related info and international coverage Summary News
AZN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AZN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options